Company intelligence / Profile preview
Shanxi Pude Pharmaceutical
Datong, Shanxi, Chinapudepharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Shanxi Pude Pharmaceutical has at least two small molecule pain drugs at advanced clinical or approved stages in China: flurbiprofen axetil (COXs, for cancer pain, highest phase 3) and dexketoprofen trometamol (COX-1 x COX-2, for low back pain and postoperative pain, highest phase 3)[5]. Clinical trial activity continues for these agents.
- Therapeutic areas
- OncologyNeurologyRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Shanxi Pude Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanxi Pude Pharmaceutical.